ONCO

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

3 - Onconetix, Inc. (0001782107) (Issuer)

425 - Onconetix, Inc. (0001782107) (Subject)

Vinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 09, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix's previously announced pending acquisition. On April 8, 2026, Realbotix announced that it has delivered its first Vinci-equipped humanoid robot to Ericsson. Vinci is a patented AI vision system that allows the robot to recognize

425 - Onconetix, Inc. (0001782107) (Subject)

Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 02, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix's previously announced pending acquisition. On April 1, 2026, Realbotix announced that it expects to deliver 19 previously ordered robots and corresponding AI implementations for months of March, April, and

425 - Onconetix, Inc. (0001782107) (Subject)

Experienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") today announced the appointment of David White as Chief Executive Officer, effective March 18, 2026, and the appointment of Sammy Dorf as a member of the Company's Board of Directors and the Audit Committee, effective March 19, 2026. Karina Fedasz, the Company's outgoing Interim Chief Executive Officer, will continue to serve as its Interim Chief Financial Officer. These appointments reflect the Company's commitment to assembling experien

DEF 14A - Onconetix, Inc. (0001782107) (Filer)

3 - Onconetix, Inc. (0001782107) (Issuer)

3 - Onconetix, Inc. (0001782107) (Issuer)

425 - Onconetix, Inc. (0001782107) (Subject)

8-K/A - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that its Board of Directors (the "Board of Directors" or "Board") has approved a 1-for-5 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on March 25, 2026. On February 3, 2026, Onconetix held a special meeting of stockholders (the "Special Meeting"), at which the Company's stockholders approved a proposal to effect a reverse split, at a ratio in

PRE 14A - Onconetix, Inc. (0001782107) (Filer)

10-K - Onconetix, Inc. (0001782107) (Filer)

425 - Onconetix, Inc. (0001782107) (Subject)

8-K - Onconetix, Inc. (0001782107) (Filer)

A leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America  CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), (formerly Blue Water Biotech Inc), and Realbotix LLC. ("Realbotix"), a wholly-owned subsidiary of Realbotix Corp. (TSXV:XBOT) ("Realbotix Parent "), today announced the signing of a definitive share exchange agreement pursuant to which Onconetix will acquire 100% of the issued and outstanding equity interests of Realbotix in an all-stock transaction. Realbotix LLC is Realbotix Corp's subsidiary that is focused on researching, designing, bu

Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Parent Company"), a leader in AI-powered humanoid robots, announces it has entered into a definitive agreement with Onconetix, Inc (NASDAQ:ONCO) ("ONCO"), pursuant to which ONCO will acquire 100% of Realbotix, LLC ("RealLLC" or the "Subsidiary"), a wholly owned subsidiary of Realbotix in an all-stock transaction. RealLLC is a Nevada based wholly owned subsidiary of Realbotix. RealLLC focuses on the research, development, design and manufacture of AI-powered humanoid robots for use by commercial clients in consumer facing roles such as customer service, healthcare, education, hospitality and entertainment. Rea

8-K - Onconetix, Inc. (0001782107) (Filer)

DEF 14A - Onconetix, Inc. (0001782107) (Filer)